Last month GSK alliance with Pfizer for collaboration for HIV drugs was part of the news stand and this week again GSK made headlines by announcing its collaboration with Concert Pharmaceutical. In this deal Concert will be receiving around $35 million in upfront payments, including a $16.7 million equity investment and GSK will get CTP-518, a protease inhibitor for the treatment of HIV which is expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert's pipeline..........I think its time for Gilead and BMS to develop and add more Drugs in their existing drug discovery pipeline, so that in the coming decades these companies will be able to sustain their position in HIV domain.
No comments:
Post a Comment